A citation-based method for searching scientific literature

Alice T Shaw, Benjamin J Solomon, Rita Chiari, Gregory J Riely, Benjamin Besse, Ross A Soo, Steven Kao, Chia-Chi Lin, Todd M Bauer, Jill S Clancy, Holger Thurm, Jean-Francois Martini, Gerson Peltz, Antonello Abbattista, Sherry Li, Sai-Hong Ignatius Ou. Lancet Oncol 2019
Times Cited: 135







List of co-cited articles
1111 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung.
Agnes Balla, Farrah Khan, Kenneth J Hampel, Dara L Aisner, Nikoletta Sidiropoulos. Cold Spring Harb Mol Case Stud 2018
7
14

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
Nasser Hanna, Frances A Shepherd, Frank V Fossella, Jose R Pereira, Filippo De Marinis, Joachim von Pawel, Ulrich Gatzemeier, Thomas Chang Yao Tsao, Miklos Pless, Thomas Muller,[...]. J Clin Oncol 2004
1

Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer.
Hong Tao, Liang Shi, Aoxue Zhou, Hongxia Li, Fei Gai, Zhan Huang, Nanying Che, Zhe Liu. Lung Cancer 2020
10
10

Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC.
Daniela Ferreira, Juliana Miranda, Paula Martins-Lopes, Filomena Adega, Raquel Chaves. Int J Mol Sci 2021
2
50

Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis.
Fengzhi Zhao, Meng Xu, Honcho Lei, Ziqi Zhou, Liang Wang, Ping Li, Jianfu Zhao, Penghui Hu. PLoS One 2015
40
2

Clinicopathological and Prognostic Significance of EML4-ALK Rearrangement in Patients with Surgically Resected Lung Adenocarcinoma: A Propensity Score Matching Study.
Jinghan Shi, Weiqing Gu, Yanfeng Zhao, Junjie Zhu, Gening Jiang, Minwei Bao, Jingyun Shi. Cancer Manag Res 2020
6
16

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients.
Gee-Chen Chang, Tsung-Ying Yang, Kun-Chieh Chen, Kuo-Hsuan Hsu, Yen-Hsiang Huang, Kang-Yi Su, Sung-Liang Yu, Jeng-Sen Tseng. Sci Rep 2020
12
8

Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib.
Rafal Dziadziuszko, Tiffany Hung, Kun Wang, Voleak Choeurng, Alexander Drilon, Robert C Doebele, Fabrice Barlesi, Charlie Wu, Lucas Dennis, Joel Skoletsky,[...]. Mol Oncol 2022
1
100

Brain metastases in oncogene-driven non-small cell lung cancer.
Makoto Nishino, Kenzo Soejima, Tetsuya Mitsudomi. Transl Lung Cancer Res 2019
23
4

The role of chemotherapy in brain metastases.
M J van den Bent. Eur J Cancer 2003
74
1

A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity.
Hossam Kadry, Behnam Noorani, Luca Cucullo. Fluids Barriers CNS 2020
103
1

X-ray irradiation induces disruption of the blood-brain barrier with localized changes in claudin-5 and activation of microglia in the mouse brain.
Yukari Yoshida, Yukihiko Sejimo, Masashi Kurachi, Yasuki Ishizaki, Takashi Nakano, Akihisa Takahashi. Neurochem Int 2018
10
10

Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.
Mark K Doherty, Grzegorz J Korpanty, Pascale Tomasini, Moein Alizadeh, Kevin Jao, Catherine Labbé, Celine M Mascaux, Petra Martin, Suzanne Kamel-Reid, Ming-Sound Tsao,[...]. Radiother Oncol 2017
35
2

Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.
Suchit H Patel, Andreas Rimner, Amanda Foster, Zhigang Zhang, Kaitlin M Woo, Helena A Yu, Gregory J Riely, Abraham J Wu. Lung Cancer 2017
24
4

Cranial irradiation alters the brain's microenvironment and permits CCR2+ macrophage infiltration.
Josh M Morganti, Timothy D Jopson, Sharon Liu, Nalin Gupta, Susanna Rosi. PLoS One 2014
67
1

Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study.
Denis Moro-Sibilot, Egbert Smit, Javier de Castro Carpeño, Krzysztof Lesniewski-Kmak, Joachim G Aerts, Rosa Villatoro, Kees Kraaij, Karim Nacerddine, Yulia Dyachkova, Karen T Smith,[...]. Lung Cancer 2015
40
2

HER2 gene mutations in non-small cell lung carcinomas: concurrence with Her2 gene amplification and Her2 protein expression and phosphorylation.
Mikiko Suzuki, Kouya Shiraishi, Akihiko Yoshida, Yoko Shimada, Kenji Suzuki, Hisao Asamura, Koh Furuta, Takashi Kohno, Koji Tsuta. Lung Cancer 2015
45
2

Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03).
Gianfranco A Pesce, Dirk Klingbiel, Karin Ribi, Abderahim Zouhair, Roger von Moos, Marc Schlaeppi, Clemens B Caspar, Natalie Fischer, Sandro Anchisi, Solange Peters,[...]. Eur J Cancer 2012
60
1

ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.
Laura Q M Chow, Fabrice Barlesi, Erin M Bertino, Martin J van den Bent, Heather A Wakelee, Patrick Y Wen, Chao-Hua Chiu, Sergey Orlov, Rita Chiari, Margarita Majem,[...]. Clin Cancer Res 2022
3
33

Response of BRAFV600E-Mutant Lung Adenocarcinoma With Brain Metastasis and Leptomeningeal Dissemination to Dabrafenib Plus Trametinib Treatment.
Gaku Yamamoto, Jun Sakakibara-Konishi, Tomoo Ikari, Hidenori Kitai, Hidenori Mizugaki, Hajime Asahina, Eiki Kikuchi, Naofumi Shinagawa. J Thorac Oncol 2019
6
16

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.
Shirish M Gadgeel, Alice T Shaw, Ramaswamy Govindan, Leena Gandhi, Mark A Socinski, D Ross Camidge, Luigi De Petris, Dong-Wan Kim, Alberto Chiappori, Denis L Moro-Sibilot,[...]. J Clin Oncol 2016
125
1

Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.
Naamit K Gerber, Yoshiya Yamada, Andreas Rimner, Weiji Shi, Gregory J Riely, Kathryn Beal, Helena A Yu, Timothy A Chan, Zhigang Zhang, Abraham J Wu. Int J Radiat Oncol Biol Phys 2014
73
1



EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?
L E L Hendriks, E F Smit, B A H Vosse, W W Mellema, D A M Heideman, G P Bootsma, M Westenend, C Pitz, G J de Vries, R Houben,[...]. Lung Cancer 2014
80
1

Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer.
Javier Cortes, Javier Rodriguez, Jose Manuel Aramendia, Esteban Salgado, Alfonso Gurpide, Jesus Garcia-Foncillas, Jose Javier Aristu, Angela Claver, Ana Bosch, Jose Maria Lopez-Picazo,[...]. Oncology 2003
98
1

Whole-Brain Radiation Therapy Versus Stereotactic Radiosurgery for Cerebral Metastases.
Haley K Perlow, Khaled Dibs, Kevin Liu, William Jiang, Prajwal Rajappa, Dukagjin M Blakaj, Joshua Palmer, Raju R Raval. Neurosurg Clin N Am 2020
3
33

Two radiation regimens and prognostic factors for brain metastases in nonsmall cell lung cancer patients.
Dirk Rades, Steven E Schild, Radka Lohynska, Theo Veninga, Lukas J A Stalpers, Juergen Dunst. Cancer 2007
28
3


Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases.
Robin Guo, Mark Schreyer, Jason C Chang, S Michael Rothenberg, Dahlia Henry, Paolo Cotzia, Mark G Kris, Natasha Rekhtman, Robert J Young, David M Hyman,[...]. JCO Precis Oncol 2019
28
3


FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.
Erica C Nakajima, Nicole Drezner, Xiaoxue Li, Pallavi S Mishra-Kalyani, Yajun Liu, Hong Zhao, Youwei Bi, Jiang Liu, Atiqur Rahman, Emily Wearne,[...]. Clin Cancer Res 2022
6
16




A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
Jin-Ji Yang, Jian Fang, Yong-Qian Shu, Jian-Hua Chang, Gong-Yan Chen, Jian Xing He, Wei Li, Xiao-Qing Liu, Nong Yang, Caicun Zhou,[...]. Invest New Drugs 2021
7
14

Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review.
Loay Kassem, Kyrillus S Shohdy, Shaimaa Lasheen, Omar Abdel-Rahman, Ahmad Ali, Raafat R Abdel-Malek. Crit Rev Oncol Hematol 2019
22
4

Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
Alexis Cortot, Xiuning Le, Egbert Smit, Santiago Viteri, Terufumi Kato, Hiroshi Sakai, Keunchil Park, D Ross Camidge, Karin Berghoff, Soetkin Vlassak,[...]. Clin Lung Cancer 2022
1
100

Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients.
M Ilie, E Long, V Hofman, B Dadone, C H Marquette, J Mouroux, J M Vignaud, H Begueret, J P Merlio, D Capper,[...]. Ann Oncol 2013
88
1

Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives.
Evgeny N Imyanitov, Aglaya G Iyevleva, Evgeny V Levchenko. Crit Rev Oncol Hematol 2021
68
1

Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer.
Luping Lin, Saurabh Asthana, Elton Chan, Sourav Bandyopadhyay, Maria M Martins, Victor Olivas, Jenny Jiacheng Yan, Luu Pham, Mingxue Michelle Wang, Gideon Bollag,[...]. Proc Natl Acad Sci U S A 2014
71
1

Pathways downstream of Shc and Grb2 are required for cell transformation by the tpr-Met oncoprotein.
E D Fixman, T M Fournier, D M Kamikura, M A Naujokas, M Park. J Biol Chem 1996
105
1

Immunotherapy in non-small cell lung cancer harbouring driver mutations.
Alfredo Addeo, Antonio Passaro, Umberto Malapelle, Giuseppe Luigi Banna, Vivek Subbiah, Alex Friedlaender. Cancer Treat Rev 2021
17
5

The histopathology of BRAF-V600E-mutated lung adenocarcinoma.
Samuel A Yousem, Marina Nikiforova, Yuri Nikiforov. Am J Surg Pathol 2008
69
1

KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.
Ernest Nadal, Guoan Chen, John R Prensner, Hiroe Shiratsuchi, Christine Sam, Lili Zhao, Gregory P Kalemkerian, Dean Brenner, Jules Lin, Rishindra M Reddy,[...]. J Thorac Oncol 2014
72
1

Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report.
Roxana Reyes, Clara Mayo-de-Las-Casas, Cristina Teixidó, Carlos Cabrera, Elba Marín, Ivan Vollmer, Pedro Jares, Mónica Garzón, Miguel Ángel Molina-Vila, Noemí Reguart. Clin Lung Cancer 2019
9
11

Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma.
Hidefumi Sasaki, Shigeki Shimizu, Yoichi Tani, Masayuki Shitara, Katsuhiro Okuda, Yu Hikosaka, Satoru Moriyama, Motoki Yano, Yoshitaka Fujii. Lung Cancer 2013
35
2

Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.
Frances A Shepherd, Benjamin Lacas, Gwénaël Le Teuff, Pierre Hainaut, Pasi A Jänne, Jean-Pierre Pignon, Thierry Le Chevalier, Lesley Seymour, Jean-Yves Douillard, Stephen Graziano,[...]. J Clin Oncol 2017
61
1

Precision Oncology Decision Support: Current Approaches and Strategies for the Future.
Katherine C Kurnit, Ecaterina E Ileana Dumbrava, Beate Litzenburger, Yekaterina B Khotskaya, Amber M Johnson, Timothy A Yap, Jordi Rodon, Jia Zeng, Md Abu Shufean, Ann M Bailey,[...]. Clin Cancer Res 2018
36
2


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.